NexCure, a healthcare company focused on expanding access to complex treatments, has launched with $19 million in Series A financing to support the delivery of CAR-T and other advanced therapies in community outpatient settings. The funding round was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures.
Founded by Raven, the healthcare incubator of RA Capital, NexCure aims to address a major constraint in the healthcare system: limited access to advanced therapies due to the concentration of treatment capacity at a small number of specialized hospitals. Of the roughly 6,100 hospitals in the United States, only about 200 currently administer CAR-T therapy, leaving many eligible patients unable to receive the treatment.
NexCure’s model combines purpose-built outpatient clinics with proprietary technology designed to support the operational and clinical complexity of advanced therapeutics. By shifting delivery of these therapies from large academic medical centers to community-based outpatient environments, the company aims to bring treatment closer to patients while reducing logistical, geographic, and financial barriers.
The company’s platform is designed to standardize clinical protocols, automate care coordination, and reduce operational variability across sites. The system integrates clinical decision support, remote monitoring capabilities, and operational intelligence to help providers safely administer treatments that require intensive monitoring and care management.
NexCure’s leadership team brings experience across academic medicine, healthcare operations, and advanced therapeutics. The company is chaired by founder Paul Rothman, a venture partner at Raven and former dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine. Jennifer Smith serves as CEO, bringing more than two decades of healthcare operations experience focused on scaling innovative care delivery models. Sophie Papa, an expert in cellular therapy, is co-founder and chief medical officer, and Anish More serves as co-founder and chief business officer.
The funding will help NexCure build out its operating system for delivering clinically intensive therapies in outpatient settings and expand the infrastructure needed to support next-generation treatments across broader healthcare networks.
KEY QUOTES:
“I understand first hand the impact that cell therapy can deliver for people suffering from cancer and other diseases, and we are determined to surmount the operational barriers care providers face when attempting to provide access to these life-changing treatments. NexCure is helping to solve the challenge of bringing current and future complex therapies, with high care and monitoring needs, to the patients that need them.”
Sophie Papa, FRCP, PhD — Co-founder and Chief Medical Officer, NexCure
“Today, only a fraction of patients who are eligible for CAR-T therapy actually receive it, largely due to where and how care is delivered. As CAR-T matures and moves beyond oncology into autoimmune and other diseases,NexCure will work in partnership with the health ecosystem to thoughtfully expand access so more patients can receive advanced therapies in settings that are safe, effective and closer to home.”
Paul Rothman, MD — Founder and Board Chair, NexCure; Venture Partner at Raven, RA Capital’s Healthcare Incubator
“CAR-T and advanced oncology therapies are at a historic breakthrough moment, but the infrastructure to deliver them hasn’t kept pace. We are excited to invest in NexCure as they solve that bottleneck with a scalable outpatient clinic model that expands access, increases efficiency, and redefines where advanced therapeutics can be safely and efficiently delivered.”
Ben Freeberg — Founder and Managing Partner, Oncology Ventures
